Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nabilone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 12/20 | 1.00 |
| ▸ | CNR2 | P34972 | 14/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nabilone SCHEMBL33339 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL17223864 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL29475614 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL11268571 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL2762240 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL13759779 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL11615666 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL29448222 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL15520922 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL11615083 | 0.99 | CNR2 (0.98) | CNR2CNR1NR1I2ADORA3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021042001-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | Natural Extraction Systems, LLC (US) | 2021-03-04 | — | — | WO | claimed |
| EP-3446681-B1 | ABUSE RESISTANT CAPSULE | SCHERER TECHNOLOGIES LLC R P (US) | 2020-12-23 | — | — | EP | claimed |
| EP-2968129-B1 | ABUSE RESISTANT CAPSULE | SCHERER TECHNOLOGIES LLC R P (US) | 2018-09-05 | — | — | EP | claimed |
| US-20120202891-A1 | Cannabinoid-Containing Compositions and Methods for Their Use | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-08-09 | — | — | US | claimed |
| EP-0004753-B1 | PREPARATION OF TETRAHYDROBENZOXOCINS AND CIS-HEXAHYDRODIBENZOPYRANONES | ELI LILLY AND COMPANY (US) | 1982-05-26 | — | — | EP | claimed |
| US-4278603-A | SEDATIVES, ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1981-07-14 | — | — | US | claimed |
| US-4148809-A | Process for preparing dl-cis-1-hydroxy-3-substituted-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-ones | ELI LILLY AND COMPANY (US) | 1979-04-10 | — | — | US | claimed |
| US-4102902-A | Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor | ELI LILLY AND COMPANY (US) | 1978-07-25 | — | — | US | claimed |
| US-4054582-A | Process for converting cis-hexahydrodibenzo[b,d]pyran-9-ones to trans-hexahydrodibenzo[b,d]-pyran-9-ones | ELI LILLY AND COMPANY (US) | 1977-10-18 | — | — | US | claimed |
| US-4054581-A | Preparation of cis-1-hydroxy-3-substituted-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-ones and intermediates therefor | ELI LILLY AND COMPANY (US) | 1977-10-18 | — | — | US | claimed |
| US-3988439-A | Dibenzo[b,d]pyranone dispersions | ELI LILLY AND COMPANY (US) | 1976-10-26 | — | — | US | claimed |
| US-20260083161-A1 | CONTAINERS THAT CONTAIN ANIONIC CANNABINOIDS | NATURAL EXTRACTION SYS LLC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4667001-A2 | FORMULATIONS OF CANNABINOIDS | ADD Advanced Drug Delivery Technologies Ltd. (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-12484606-B2 | Compositions and methods related to anionic cannabinoid molecules | Natural Extraction Systems, LLC (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4074307-B1 | FORMULATIONS OF CANNABINOIDS | ADD ADVANCED DRUG DELIVERY TECH LTD (CH) | 2025-11-12 | — | — | EP | disclosed |
| US-3988439-A | Dibenzo[b,d]pyranone dispersions | ELI LILLY AND COMPANY (US) | 1976-10-26 | — | — | US | disclosed |
| US-3987188-A | Hexahydro-dibenzo[b,d]pyran-9-ones as sedative drugs | ELI LILLY AND COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
| US-3968125-A | Dihydroxyhexahydrodibenzo[b,d]pyrans | ELI LILLY AND COMPANY (US) | 1976-07-06 | — | — | US | disclosed |
| US-3953603-A | Hexahydro-dibenzo[b,d,]pyran-9-ones as psychotropic, particularly anti-depressant drugs | ELI LILLY AND COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
| US-3944673-A | Hexahydro-dibenzo[b,d]pyran-9-ones as analgesic drugs | ELI LILLY AND COMPANY (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083161-A1 | CONTAINERS THAT CONTAIN ANIONIC CANNABINOIDS | CNR2, CNR1, OPRD1 | CNR1 2/4885CNR2 1/4885NR1I2 3129/4885 |
| US-12484606-B2 | Compositions and methods related to anionic cannabinoid molecules | CNR2, CNR1, PHOSPHO1 | CNR1 2/4885CNR2 1/4885NR1I2 2621/4885 |
| US-20120202891-A1 | Cannabinoid-Containing Compositions and Methods for Their Use | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885NR1I2 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.